Delivery Order SPE2DB20D9127-SPE2DB25FPRJ5
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $63,801.78 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, awarded on August 7, 2025, with an ultimate completion date of August 28, 2025, represents a specific supply requirement fulfilled under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA. The...
- The Defense Logistics Agency awarded a delivery order valued at $91,145.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a targeted pharmaceutical procurement to support Department of Defense healthcare operations. The award carries no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $9,114.54 to DMS Pharmaceutical Group Inc. for Perjeta 420 mg/14 ml vials on August 14, 2025, with an ultimate completion date of September 5, 2025. This firm fixed-price delivery order represents a pharmaceutical supply requirement with no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, is the prime contractor on this award. The delivery...
- The Defense Logistics Agency awarded a delivery order valued at $136,717.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The contract is a firm fixed-price delivery order with an ultimate completion date of September 29, 2025, and was awarded on September 8, 2025. This award was issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract, valued at $8,509.92, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of the oncology drug Perjeta (pertuzumab) 420 mg/14 mL vial, with an ultimate completion date of October 10, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $27,343.62 on July 28, 2025, for the supply of Perjeta 420 mg/14 mL vials. The contract, which carries no set-aside designation, is funded by the Defense Logistics Agency's Medical Supply Chain and is scheduled for completion by August 18, 2025. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite...
- The U.S. Defense Logistics Agency (DLA) through its Medical Supply Chain awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The delivery order, valued at $27,343.62 with a firm fixed-price contract type, carries an ultimate completion date of July 9, 2025, and was awarded on June 16, 2025. This award does not utilize any set-aside designation,...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $41,015.34 by the Defense Logistics Agency's Medical Supply Chain on August 18, 2025. The delivery order, which concludes on September 9, 2025, calls for the supply of Perjeta 420 mg/14 mL vials to support Department of Defense healthcare requirements. This award was issued without a set-aside designation, allowing DMS...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $25,529.76 contract is for the delivery of 420 mg/14 ml vials of the cancer drug Perjeta, with a performance period through December 12, 2024. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $12,764.88 firm fixed-price delivery order is for the supply of a 420 mg/14 ml vial of the oncology medication Perjeta. The award is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This IDC allows the DLA to...
- SPE2DB20D9127Indefinite Delivery Contract
- SPE2DB20D9127-SPE2DB25FPRJ5Delivery Order
The Defense Logistics Agency awarded a $31,900.82 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 420 mg/14 mL vials of Perjeta, an oncology treatment medication. The award was issued on September 8, 2025, with an ultimate completion date of September 29, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, which is valued at $499.999 billion and remains valid through November 2026. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its woman-owned small business status to compete effectively for DLA contracts across diverse medical product categories. The company's robust portfolio includes branded and generic prescription drugs, biologics, and specialty pharmaceutical products supporting military health facilities nationwide. This delivery order for Perjeta demonstrates the company's continued role in supplying specialized oncology medications to Department of Defense healthcare sites as part of its comprehensive pharmaceutical distribution services.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $31.9k | 9/8/25 |